MétaCan
Menu
Back to cohort
Record W4415421189 · doi:10.1080/14796708.2025.2568367

Key results from a review of the abuse potential of lemborexant in patients with insomnia: a plain language summary

2025· review· en· W4415421189 on OpenAlexaff
Margaret Moline, Beatrice Setnik, Judy Ashworth, Jack E. Henningfield

Bibliographic record

VenueFuture Neurology · 2025
Typereview
Languageen
FieldPsychology
TopicSleep and related disorders
Canadian institutionsAltasciences (Canada)University of Toronto
FundersEisai IncorporatedEisai
KeywordsPlain languageKey (lock)Plain EnglishSuicide preventionPoison controlPlain text

Abstract

fetched live from OpenAlex

Plain Language SummaryWhat is this summary about?Lemborexant is medication prescribed for the treatment of insomnia, a disorder where people have trouble falling asleep and/or staying asleep. Lemborexant is a type of medication called a dual orexin-receptor antagonist (DORA). Since lemborexant acts on the central nervous system, it is important to understand whether there is potential for abuse. Abuse potential can be assessed using the United States Controlled Substances Act ‘8-factor analysis’. This review discusses what is known about lemborexant according to each of the 8 factors.What did the researchers find?Lemborexant did not show risk of abuse in nonclinical (animal) testing, but did show risk of abuse in a human abuse potential study. Like other similar medications (other DORAs like suvorexant and daridorexant), people who use sedatives recreationally found lemborexant to be ‘likeable’. However, internet surveillance suggests that DORA drugs have very low abuse-related risks in the community. Further, lemborexant did not produce withdrawal symptoms in phase 3 clinical trials, had no abuse-related side effects (such as euphoria) with approved doses, provided significant benefits on sleep, and didn’t cause next-morning effects (lingering feelings or side effects the morning after taking a sleep medication).What do the findings mean?Like most prescription insomnia medications, lemborexant was placed into Schedule IV as a controlled substance. However, the collective evidence described here suggests that DORAs, including lemborexant, may be less likely to be abused in the real world, thereby having lower risks to public health, than sedative-hypnotic drugs. If ongoing postmarketing data (ongoing since the time of the article’s original publication in February 2023) demonstrate that lemborexant is associated with lower rates of abuse than other Schedule IV hypnotics, then reducing lemborexant to a Schedule V substance or removing the scheduling of lemborexant altogether may be in the interest of public safety.How to say (download PDF and double click sound icon to play sound)…Lemborexant: lem-bow-rex-antInternet surveillance: The monitoring and collecting of information about an individual’s online activity. In this study, internet surveillance refers to information collected from individuals on popular online forums frequented by users of recreational drugs.Phase 3 clinical trial: A clinical study conducted in humans that tests how safe and how well a new medicine works compared with a standard treatment.Sedative-hypnotic: A medicine that slows down brain activity, leading to sedation (i.e., a calming effect) or inducing sleep (i.e., hypnotic)Schedule IV: Substances in this category have a lower potential for abuse compared with substances in the Schedule III category; however, despite their lower abuse potential, Schedule IV substances still carry a potential risk for physical or psychological dependence.This is an abstract of the Plain Language Summary of Publication article.View the full Plain Language Summary PDF of this article to read the full-textLink to original article here

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: Review
Teacher disagreement score0.874
Threshold uncertainty score0.953

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0020.000
Bibliometrics0.0000.001
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0010.000
Research integrity0.0010.001
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.005
GPT teacher head0.254
Teacher spread0.250 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueFuture NeurologySame topicSleep and related disordersFrench-language works237,207